This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
ASCO GU 2021
Go
Reset
Send Date
Subject
Created Date
ID
Asc
Desc
How Radioligand Therapy Is Shaping Advanced Prostate Cancer Treatment – ASCO GU 2025
Sent on 18 February 2025
ASCO GU 2025 Treatment Intensification, Radiopharmaceuticals, and Real-World Evidence in Prostate Cancer
Sent on 14 February 2025
ASCO Genitourinary Cancers Symposium Session Highlights Start Thursday, Feb 17 - ASCO GU 2022
Sent on 11 February 2022
Looking Forward to ASCO GU 2022 - What to Expect in Prostate, Kidney, and Bladder Cancer
Sent on 06 January 2022
Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer in a Prospective Statewide Collaborative
Sent on 12 November 2021
Kidney Cancer Association’s International Kidney Cancer Symposium 2021 Meeting Highlights
Sent on 07 November 2021
The Degree of PSA Response Is Strongly Associated with Survival Outcomes in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) from the PROSPER Trial
Sent on 12 March 2021
Putting Practice-Changing Data into Practice - Advanced Urothelial Carcinoma
Sent on 03 March 2021
Molecular Correlates of Response to Apalutamide in nmCRPC and Androgen Annihilation Treatment Strategy with Abiraterone and Apalutamide in Chemo-Naïve mCRPC
Sent on 02 March 2021
Evaluating Treatments in Advanced GU Malignancies
Sent on 19 February 2021
Progress in Treatment Personalization for Advanced Prostate Cancer
Sent on 18 February 2021
Evaluating Combination Treatment Approaches in Metastatic Castration-Resistant Prostate Cancer
Sent on 16 February 2021
Advances in the Treatment of Bladder Cancer - ASCO GU 2021
Sent on 15 February 2021
Advances in Therapies for Kidney Cancer from the 2021 Genitourinary Cancers Symposium
Sent on 13 February 2021
Navigating Treatments of Prostate Cancer - ASCO GU 2021 Highlights
Sent on 12 February 2021
The Progress and Promise in Treatments for Locally Advanced and Metastatic Urothelial Carcinoma - ASCO GU 2021
Sent on 12 February 2021
The Progress and Promise in the Treatment of Prostate Cancer - ASCO GU 2021
Sent on 11 February 2021
ASCO GU 2021 Research in the News on Bladder and Kidney Cancer
Sent on 08 February 2021
ASCO GU 2021 Prostate Cancer Sessions Starting Thursday, February 11
Sent on 07 February 2021
Display #
5
10
15
20
25
30
50
100
Results 1 - 19 out of 19
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free